AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Jasper Therapeutics, Inc.
Video analysis: JSPR
All videosNo video analysis for this stock yet. Request one from our team.
News: JSPR
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C.
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
Jasper Closes Kira Deal, Extends Cash Runway
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases.
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
